A Cure for Zika, Ebola, and Even AIDS?
An even bigger problem than the Zika virus... Even better than a vaccine... A cure for Zika, Ebola, and even AIDS?...
According to a new report in the Wall Street Journal, about 15 companies are currently "scrambling" to develop a vaccine for the frightening Zika virus...
As we discussed last week, Zika is spread primarily by mosquitoes, and has reportedly reached "pandemic" levels in South and Central America. The virus has been linked to a serious birth defect – microcephaly – in babies of mothers who have been infected while pregnant.
And according to a recent study in prestigious British medical journal The Lancet, Zika could also be linked to a rare but potentially deadly immune condition in adults known as Guillain-Barré syndrome.
The Journal reports that most of these vaccines are in just the first stages of development. So it could take until the end of 2017 for one to be approved for use.
Stansberry Venture editor Dave Lashmet agrees... Under the usual process, it would typically take another 18 to 24 months for a vaccine to be approved. But that may not be the case this time...
Dave has identified one tiny drugmaker that has already developed a Zika vaccine. This vaccine has been shown to work in mice, and is in large-animal testing now.
Because there is currently no treatment for Zika, Dave says animal testing and a small human safety trial could be enough to gain U.S. Food and Drug Administration approval. This means "provisional" approval could be granted in less than one year.
Of course, as we mentioned last week, Stansberry Venture subscribers may not have to wait even that long to profit... If the vaccine works as expected, a big vaccine maker is virtually guaranteed to buy this tiny company at a huge premium.
In the meantime, the Journal says the rush to slow the spread of Zika highlights an even bigger problem. In short, there are still no vaccines for many of the world's biggest health threats.
Despite killing as many as 1 million people per year, there is no vaccine for malaria. There is still no vaccine for Ebola. There's no vaccine for Zika. And there is likely no vaccine for whatever virus comes next. From the article...
Epidemics are unpredictable, making for an uncertain revenue stream, and often erupt in poor parts of the world. Health officials are aware that current research and development processes are ill-suited for epidemic diseases and have begun working on changes in the wake of the Ebola crisis.
Fortunately, if Dave's research is correct, something even better than a vaccine could be coming...
As regular Digest readers know, this tiny drugmaker isn't just developing a preventative vaccine for Zika. Dave says it's also working on something completely different... a potentially "world-changing" medicine... a potential "antidote" to viral infections. As Dave explained it to his Stansberry Venture subscribers...
Most viral infections are untreatable: When a virus attacks your body, your immune system is on its own to fight off the bug. If it succeeds, you recover. Otherwise, it can fight the virus to a stalemate – leaving you with a chronic condition – or it fails, and the virus eventually kills you. Regardless, no pill will help make the virus go away.
We've made great progress lately with hepatitis C. And acquired immune deficiency syndrome (AIDS) is now controllable if you can tolerate seven different classes of drugs. But broadly speaking, we have never had an equivalent to antibiotics or antifungals when it comes to viruses. Until now...
In simple terms – just like antibiotics can treat and cure many different kinds of bacterial infections, and antifungals can treat and cure many different kinds of fungal infections – this technology could potentially treat and cure many different kinds of viruses.
This is a "second-generation" product which could cure viruses after you're infected. Incredibly, Dave says it could potentially cure any viral infection from Ebola to HIV... even newly emerging viruses and terror threats (although this science is still being proven out).
If this technology does work, the company will be much more valuable than even Dave can project. Nothing like this has ever been possible before. It's the cutting edge of medicine. Dave says it's still years away from development... but early data is positive, and this technology is too powerful to ignore. It could literally change the world of medicine.
As we mentioned last week, despite this new technology and the recent news of its Zika vaccine, this tiny company is still trading below Dave's maximum buy price. But the stock has been moving higher, and it may not remain below the buy-up-to price for much longer.
Out of the 11 recommendations Dave made in 2015, four companies soared 100% or more just days or weeks later.
You can get immediate access to all of Dave's research with a 100% risk-free trial subscription to Stansberry Venture. Click here to learn more.
New 52-week highs (as of 3/7/16): Deutsche Bank Gold Double Long Fund (DGP), Market Vectors Junior Gold Miners Fund (GDXJ), SPDR Gold Shares Fund (GLD), Kaminak Gold (KAM.V), NovaGold Resources (NG), OceanaGold (OGC.TO), Reservoir Minerals (RMC.V), Seabridge Gold (SA), Sysco (SYY), and AT&T (T).
In today's mailbag, big praise for the latest piece from contributing editor P.J. O'Rourke... more comments on our Bear Market Survival Program... and several more subscribers respond to Porter's request from the Friday Digest.
"What. A. Coup... for you to have brought P.J. O'Rourke on board. It is such a treat to get a short essay from Peej in the Digest. Thank you!" – Paid-up subscriber Kurt Silver
"[Yesterday's] piece on politics by P.J. is a classic! He tells it like it is, unfortunately. He is a positive addition to the Digest, a definite keeper." – Paid-up subscriber Dell Allen
"Go get 'em, P.J... best column yet!" – Paid-up subscriber Joe G.
"Although your insight, guidance, and opinions are important, please, please do not stop adding P.J. O'Rourke to your letter. He's a hoot. The one today on politics and politicians is a classic!!" – Paid-up subscriber Tom B.
"Porter, life (and the virus from hell) has a unique way to humble us, as you experienced last week. Keep up the great work. 'See you' next Friday." – Paid-up subscriber Kevin M. Kelly
"Porter – your Bear Market Survival Program was incredibly valuable! I am writing to let you know that your training does pay off. For years I was a 'buy and fold' investor. I have now been with you for several years, and I have made the greatest gains of my lifetime. I have gained experience shorting stocks, buying options, holding some gold and silver bullion, recognizing value in equities, and value in distressed credit. I am lightyears ahead of where I was several years ago. So I am really writing this note just to say 'Thank You.'" – Paid-up subscriber Dennis Harper
"Porter, I have been a Flex subscriber for years (and I only change subscriptions 1 or 2 times a year) but I am not writing to you about that just now. I want you to know that your special Friday essays have been of prime importance to me ever since I became a subscriber to Stansberry Research. If I had no money to invest, I would still never want to miss one of them!
"Many times you started by writing that what you were about to tell us would result in lots of cancellations. I can assure you, that in my case at least, nothing could be further from the truth. In my opinion, you are an exceptionally clear thinker and communicator, and you know what is most important for us to know. I carefully underline and reread and implement your Friday essays.
"Some persons may resign because of them, but I, and surely many other subscribers treat them as the treasure that they are!! Also, your annual report card is the most incontrovertible proof of your commitment to both excellence and transparency! In the past, I have read other companies' investment newsletters. No more. Stansberry Research is the best, and has my trust and gratitude. Thank you Porter, and all of your wonderful staff!!!" – Paid-up subscriber Daniel S.
"I love the insight and education of Friday Digests. I love your belief of giving us what you would like to know if our roles were reserved. It is inspiring to see this knowledge in practice. It is so powerful to feel this experience firsthand that I always try to do this in my own life. I try to give others what I would like to receive. Thank you Porter!" – Paid-up subscriber Krzysztof K.
"Porter, If there are any emails I save, it is the Friday Digests. Why? Because when I give you my money via my yearly subscriptions, I trust you. When your mantra is; 'if roles were reversed...' I know what I'm reading, and what you suggest I read and learn (there is only learning, not teaching) is your honest desire for others to have success. It seems to be an act of irony. On the one hand you are honest about making money through your subscribers, yet on the other hand you want us to succeed. In this narcissistic country we live in, your Friday Digests prove the contrary. By giving away, you can gain. Thank you for your Fridays!" – Paid-up subscriber PK
"Porter, Just add my voice to those who appreciate your candid thoughts on Friday. I'm old so my horizon's short, and I have too little money to use a lot of the tools your services offer. But I value my connection with you, and I like the perspective you give on the markets, on the world, and on life. I know I'll never sever that connection, so I have just signed up for your lifetime service, happy that I'll continue to get the Friday Digest. For all you do, with such decency and sound ethics, thanks." – Paid-up subscriber George Miller
Regards,
Justin Brill
Baltimore, Maryland
March 8, 2016
|